SCHEMBL1122142

SCHEMBL1122142

CC[C@H](C)OC(=O)[C@@H](C)c1ccc2cc(OC)ccc2c1

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.74
L3MBTL1 Q9Y468 1/20 0.74
AKR1C3 P42330 7/20 0.62
AKR1C2 P52895 7/20 0.62
PTGS2 P35354 5/20 0.62
PTGS1 P23219 3/20 0.62
TSHR P16473 2/20 0.62
CDC42 P60953 1/20 0.62
RAC1 P63000 1/20 0.62
CYP1A2 P05177 1/20 0.62
SLC22A6 Q4U2R8 1/20 0.62
LMNA P02545 1/20 0.59
MAPT P10636 1/20 0.59
CYP2C9 P11712 1/20 0.59
AKR1C1 Q04828 1/20 0.58
ABCB11 O95342 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10406806 1.00 TDP1 (0.74) TDP1L3MBTL1AKR1C3AKR1C2PTGS2
SCHEMBL10407187 0.89 TDP1 (0.71) TDP1L3MBTL1AKR1C3AKR1C2PTGS2
SCHEMBL10407191 0.88 TDP1 (0.72) TDP1L3MBTL1AKR1C3AKR1C2PTGS2
SCHEMBL10407192 0.87 TDP1 (0.67) TDP1L3MBTL1AKR1C3AKR1C2PTGS2
SCHEMBL9284416 0.85 TDP1 (1.00) TDP1L3MBTL1AKR1C3AKR1C2PTGS2
SCHEMBL506523 0.84 TDP1 (0.71) TDP1L3MBTL1AKR1C3AKR1C2PTGS2
SCHEMBL31619540 0.84 TDP1 (0.71) TDP1L3MBTL1AKR1C3AKR1C2PTGS2
SCHEMBL3280876 0.84 TDP1 (0.71) TDP1L3MBTL1AKR1C3AKR1C2PTGS2
SCHEMBL221436 0.84 TDP1 (0.71) TDP1L3MBTL1AKR1C3AKR1C2PTGS2
SCHEMBL9717784 0.83 TDP1 (0.78) TDP1L3MBTL1AKR1C3AKR1C2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5709847-A TOPICAL APPLICATION TO PREVENT DAMAGE TO SKIN BY ACCUTE ORCHRONIC UV EXPOSURE THE PROCTER & GAMBLE COMPANY (US) 1998-01-20 US claimed
US-5384115-A Photoprotection compositions comprising a radical scavenging compound and an anti-inflammatory agent THE PROCTER & GAMBLE COMPANY (US) 1995-01-24 US claimed
US-4912248-A A 2-naphthyl containing ester THE PROCTER & GAMBLE COMPANY (US) 1990-03-27 US claimed
US-20170173004-A1 Methods For Treating Inflammatory Conditions CAVALRY FUND I LP 2017-06-22 US disclosed
US-9408844-B2 Methods for treating inflammatory conditions MELIOR DISCOVERY, INC. (US) 2016-08-09 US disclosed
CN-104219952-A Skin lightening compositions LASYA INC 2014-12-17 CN disclosed
EP-2800470-A1 SKIN LIGHTENING COMPOSITIONS Merz North America, Inc. (US) 2014-11-12 EP disclosed
US-20140227209-A1 Methods For Treating Inflammatory Conditions MELIOR DISCOVERY, INC. (US) 2014-08-14 US disclosed
US-8716294-B2 Methods for treating inflammatory conditions MELIOR DISCOVERY, INC. (US) 2014-05-06 US disclosed
US-20130224137-A1 SKIN LIGHTENING COMPOSITIONS LASYA, INC. (US) 2013-08-29 US disclosed
WO-2013103874-A1 SKIN LIGHTENING COMPOSITIONS LASYA, INC. (US) 2013-07-11 WO disclosed
US-4869897-A SUNCREEN AGENTS THE PROCTER & GAMBLE COMPANY (US) 1989-09-26 US disclosed
US-4847069-A SUNSCREEN AGENTS THE PROCTER & GAMBLE COMPANY (US) 1989-07-11 US disclosed
US-4847072-A SUNSCREEN AGENTS THE PROCTER & GAMBLE COMPANY (US) 1989-07-11 US disclosed
US-4847071-A SUNSCREEN AGENTS THE PROCTER & GAMBLE COMPANY (US) 1989-07-11 US disclosed
EP-0313305-A2 Photoprotection compositions comprising chelating agents THE PROCTER & GAMBLE COMPANY (US) 1989-04-26 EP disclosed
EP-0313303-A2 Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent THE PROCTER & GAMBLE COMPANY (US) 1989-04-26 EP disclosed
EP-0313347-A2 Photoprotection compositions comprising sorbohydroxamic acid and an anti-inflammatory agent THE PROCTER & GAMBLE COMPANY (US) 1989-04-26 EP disclosed
EP-0313302-A2 Photoprotection compositions comprising sorbohydroxamic acid THE PROCTER & GAMBLE COMPANY (US) 1989-04-26 EP disclosed
EP-0313304-A2 Photoprotection compositions comprising tocopherol sorbate THE PROCTER & GAMBLE COMPANY (US) 1989-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170173004-A1 Methods For Treating Inflammatory Conditions TSLP, TLR3, TLR4 TDP1 3039/4885L3MBTL1 2312/4885AKR1C3 1830/4885
US-20130224137-A1 SKIN LIGHTENING COMPOSITIONS CUTA, COL14A1, COLGALT1 TDP1 1929/4885L3MBTL1 1310/4885AKR1C3 2623/4885
US-20140227209-A1 Methods For Treating Inflammatory Conditions TSLP, TLR3, TLR4 TDP1 3039/4885L3MBTL1 2312/4885AKR1C3 1830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.